Physician profile
Steve E Gruer
NPI 1760526263
$5,906.64
in general payments reported to CMS, 2019-2025
24 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $696 · 2023: $1,090 · 2024: $1,616 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,826 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.65 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $869.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $770.87 | 2022-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $518.07 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $515.45 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $511.59 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $457.59 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $401.00 | 2023-2025 | |
| Genentech USA, INC. | $314.22 | 2021-2025 | Xolair |
| Biocryst US Sales Co., LLC | $299.83 | 2023-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $194.98 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $146.84 | 2021-2025 | Dupixent |
| Ionis Pharmaceuticals, INC. | $144.33 | 2025 | Dawnzera |
| Octapharma USA, INC. | $139.30 | 2023-2024 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Pfizer INC. | $135.93 | 2021-2024 | |
| Kaleo, INC. | $123.45 | 2022-2024 | Auvi-Q |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $80.67 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $80.53 | 2025 | Neffy |
| Amgen INC. | $75.89 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $24.42 | 2022 | |
| Mylan Specialty L.P. | $24.01 | 2024 | Yupelri |
| Cycle Pharmaceuticals INC | $23.06 | 2025 | Sajazir |
| Nestle Healthcare Nutrition INC. | $21.54 | 2023 | |
| Phadia US INC. | $19.22 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Gruer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.